{"transactions":[{"id":1650521,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94435,"kind":"organization","name":"Abingworth Bioventures VII LP","position":10,"cik":"0001688313","reported_name":"Abingworth Bioventures VII LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2024-02-12T18:23:53.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":190000,"price":12.95,"value":2460500.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The amount of Voting Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by Abingworth Bioventures VII LP (\"ABV VII\"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any."}],"balance_after":1066189,"source":{"system":"sec-edgar","filing":"0000950170-24-014017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000095017024014017/ownership.xml","form_type":"4"}},{"id":1771064,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94435,"kind":"organization","name":"Abingworth Bioventures VII LP","position":10,"cik":"0001688313","reported_name":"Abingworth Bioventures VII LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Prefunded Warrants","published_at":"2023-10-02T19:54:09.000Z","date":"2023-09-28","kind":"exercise","planned":false,"acquired":true,"shares":762126,"price":1.75,"value":1333720.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 28, 2023, Abingworth Bioventures VII LP (\"ABV VII\") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the \"Prefunded Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Prefunded Warrants are immediately exercisable and do not expire. However, the Prefunded Warrants contain provisions preventing the Prefunded Warrants from being exercised if such exercise would result in ABV VII beneficially owning greater than 9.99% of the Issuer's voting securities."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Prefunded Warrants are immediately exercisable and do not expire. However, the Prefunded Warrants contain provisions preventing the Prefunded Warrants from being exercised if such exercise would result in ABV VII beneficially owning greater than 9.99% of the Issuer's voting securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":762126,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":762126},"source":{"system":"sec-edgar","filing":"0000899243-23-019658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323019658/doc4.xml","form_type":"4"}},{"id":1771063,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94435,"kind":"organization","name":"Abingworth Bioventures VII LP","position":10,"cik":"0001688313","reported_name":"Abingworth Bioventures VII LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Warrants","published_at":"2023-10-02T19:54:09.000Z","date":"2023-09-28","kind":"exercise","planned":false,"acquired":false,"shares":1092056,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 28, 2023, Abingworth Bioventures VII LP (\"ABV VII\") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the \"Prefunded Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result ABV VII obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result ABV VII obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1.75,"underlying":"Common Stock","underlying_shares":1092056},"source":{"system":"sec-edgar","filing":"0000899243-23-019658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323019658/doc4.xml","form_type":"4"}},{"id":1771062,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94435,"kind":"organization","name":"Abingworth Bioventures VII LP","position":10,"cik":"0001688313","reported_name":"Abingworth Bioventures VII LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T19:54:09.000Z","date":"2023-09-28","kind":"exercise","planned":false,"acquired":true,"shares":329930,"price":1.75,"value":577377.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 28, 2023, Abingworth Bioventures VII LP (\"ABV VII\") exercised the Tranche A Warrants, which resulted in the issuance of 329,930 shares of Common Stock and 762,126 prefunded warrants to purchase common stock (the \"Prefunded Warrants\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":1531436,"source":{"system":"sec-edgar","filing":"0000899243-23-019658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323019658/doc4.xml","form_type":"4"}},{"id":1898700,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Warrants","published_at":"2023-05-10T16:30:14.000Z","date":"2023-05-08","kind":"purchase","planned":false,"acquired":true,"shares":1778000,"price":0.4425,"value":786765.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Tranche B Warrants are also immediately exercisable and expire upon the earlier of 3.5 years from the date of issuance and 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS. However, the Tranche B Warrants contain provisions preventing the Tranche B Warrants from being exercised if such exercise would result in ABV VII obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Tranche B Warrants are also immediately exercisable and expire upon the earlier of 3.5 years from the date of issuance and 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS. However, the Tranche B Warrants contain provisions preventing the Tranche B Warrants from being exercised if such exercise would result in ABV VII obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":1778000,"derivative":{"exercise_price":2.5,"underlying":"Common Stock","underlying_shares":1778000},"source":{"system":"sec-edgar","filing":"0000899243-23-012501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323012501/doc4.xml","form_type":"4"}},{"id":1898699,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":2,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":3,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":4,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":5,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":6,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":7,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":8,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":9,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Warrants","published_at":"2023-05-10T16:30:14.000Z","date":"2023-05-08","kind":"purchase","planned":false,"acquired":true,"shares":1092056,"price":0.4425,"value":483234.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result Abingworth Bioventures VII LP (\"ABV VII\") obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Tranche A Warrants are immediately exercisable and must be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of the Issuer's Study C602 and will expire if positive top-line data is not announced prior to the 3.5 year anniversary of the date of issuance. However, the Tranche A Warrants contain provisions preventing the Tranche A Warrants from being exercised if such exercise would result Abingworth Bioventures VII LP (\"ABV VII\") obtaining greater than 9.99% of the Issuer's voting securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ABV VII. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the \"Carlyle Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Carlyle Genesis UK LLC is the principal member of Abingworth LLP. ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII. Each of the Carlyle Entities may be deemed to share beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth LLP. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein."}],"balance_after":1092056,"derivative":{"exercise_price":1.75,"underlying":"Common Stock","underlying_shares":1092056},"source":{"system":"sec-edgar","filing":"0000899243-23-012501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323012501/doc4.xml","form_type":"4"}},{"id":2040902,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":3,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":4,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":5,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":6,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":7,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":8,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":9,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2023-01-31T17:24:21.000Z","date":"2023-01-27","kind":"purchase","acquired":true,"shares":3133333,"price":1.5,"value":4699999.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures VII LP (\"ABV VII\"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any."}],"balance_after":8761891,"source":{"system":"sec-edgar","filing":"0000899243-23-003059","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924323003059/doc4.xml","form_type":"4"}},{"id":2178790,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"exercise","acquired":false,"shares":9925,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Under an agreement between Kurt von Emster and Abingworth LLP, Mr. von Emster is deemed to hold the stock option and any shares of Class A Common Stock issuable upon exercise of the stock option for the benefit of ABV 8, and must exercise the stock option solely upon the direction of Abingworth LLP."}],"balance_after":0,"derivative":{"exercise_price":11,"expiration_date":"2031-05-12","underlying":"Class A Common Stock","underlying_shares":9925},"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}},{"id":2178789,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":172,"price":21.0748,"value":3624.8656,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.025 to $21.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."}],"balance_after":2960231,"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}},{"id":2178788,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":6472,"price":20.4201,"value":132158.8872,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."}],"balance_after":2960403,"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}},{"id":2178787,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":3281,"price":19.8849,"value":65242.3569,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $19.995. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."}],"balance_after":2966875,"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}},{"id":2178786,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":3316,"kind":"organization","name":"Carlyle Group Inc.","symbol":"CG","position":1,"cik":"0001527166","reported_name":"Carlyle Group Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94434,"kind":"organization","name":"Abingworth LLP","position":2,"cik":"0001397144","reported_name":"Abingworth LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124392,"kind":"organization","name":"Abingworth Bioventures 8 LP","position":3,"cik":"0001811412","reported_name":"Abingworth Bioventures 8 LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61391,"kind":"organization","name":"Carlyle Holdings I GP Inc.","position":4,"cik":"0001548626","reported_name":"Carlyle Holdings I GP Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61392,"kind":"organization","name":"Carlyle Holdings I GP Sub L.L.C.","position":5,"cik":"0001548627","reported_name":"Carlyle Holdings I GP Sub L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61393,"kind":"organization","name":"Carlyle Holdings I L.P.","position":6,"cik":"0001548628","reported_name":"Carlyle Holdings I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61394,"kind":"organization","name":"CG Subsidiary Holdings L.L.C.","position":7,"cik":"0001790577","reported_name":"CG Subsidiary Holdings L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61395,"kind":"organization","name":"TC Group, LLC","position":8,"cik":"0000933790","reported_name":"TC Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94432,"kind":"organization","name":"Carlyle Investment Management LLC","position":9,"cik":"0001354120","reported_name":"Carlyle Investment Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94433,"kind":"organization","name":"Carlyle Genesis UK LLC","position":10,"cik":"0001941860","reported_name":"Carlyle Genesis UK LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-19T16:39:43.000Z","date":"2022-08-17","kind":"exercise","acquired":true,"shares":9925,"price":11,"value":109175.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects securities held of record by Abingworth Bioventures 8 LP (\"ABV 8\"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities."}],"balance_after":2970156,"source":{"system":"sec-edgar","filing":"0000899243-22-029282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/933790/000089924322029282/doc4.xml","form_type":"4"}}]}